Organovo Holdings, Inc. (ONVO)

[RandolRocketman]

Organovo Holdings Presents Data on Modeling Liver Disease Using 3D Bioprinted Human Liver Tissue
BY MT Newswires
— 9:30 AM ET 04/12/2018

09:30 AM EDT, 04/12/2018 (MT Newswires) -- Organovo Holdings ( ONVO) was out Thursday with data on modeling non-alcoholic fatty liver disease (NAFLD) using its 3D bioprinted human liver tissues.

The company said its NAFLD disease model can now demonstrate a progressive accumulation of fat over time, creating a window of disease progression onto which candidate drugs targeted at fat accumulation and disposition can be applied.

In addition, the company said it has established that the NAFLD disease phenotype can be generated from multiple donor origin cells, and that the inherent variability between donors is reflected in the NAFLD model as variable susceptibility to tissue damage by NAFLD-promoting agents. These new data provide strong support for the application of the NAFLD model to high-value drug profiling, including the possible creation of patient or population-specific model variants, the company added.